Introduction

Abeclib 150 mg (Abemaciclib) Tablet is a precision-driven CDK4/6 kinase inhibitor designed to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology innovation, and supplied globally by Onco Solution, this medication offers targeted therapy to delay disease progression and improve survival outcomes. Clinicians trust Abeclib 150 mg (Abemaciclib) Tablet for its versatility as monotherapy or in combination with endocrine treatments, making it a cornerstone of modern breast cancer care.

Key Benefits & Indications

Abeclib 150 mg (Abemaciclib) Tablet is FDA-approved for:

1. Monotherapy: Treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer following disease progression after endocrine therapy and prior chemotherapy.
2. Combination Therapy:
   • With Aromatase Inhibitors: First-line endocrine-based therapy for postmenopausal women and men with metastatic HR+/HER2- breast cancer.
   • With Fulvestrant: For disease progression post-endocrine therapy in metastatic settings.
   • Adjuvant Use: Combined with tamoxifen or aromatase inhibitors for high-risk early breast cancer (Ki-67 score ≥20% via FDA-approved test).

By inhibiting CDK4/6 kinases, Abeclib 150 mg (Abemaciclib) Tablet disrupts cancer cell proliferation, offering a precision-driven approach to managing aggressive breast cancer subtypes.

Why Choose Abeclib 150 mg (Abemaciclib) Tablet?

• Targeted Action: Blocks CDK4/6 enzymes to halt tumor growth while sparing healthy cells.
• Clinically Proven Efficacy: Backed by Phase III trials showing prolonged progression-free survival.
• Oral Convenience: Film-coated tablet for easy administration and improved adherence.
• Global Quality Standards: Produced under WHO-GMP guidelines by Eskayef Pharmaceuticals Ltd.

Manufacturer Credibility

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, has been a pioneer in pharmaceutical excellence since 1990. Acquired from SK&F (USA), Eskayef combines decades of expertise with cutting-edge technology to produce high-quality therapies like Abeclib 150 mg (Abemaciclib) Tablet. Their WHO-GMP-certified facilities ensure compliance with global safety standards, making them a trusted partner for healthcare providers in over 40 countries. Learn more about their legacy at www.skfbd.com.

Supplier Profile: Onco Solution

Onco Solution is a leading global supplier dedicated to making life-saving cancer treatments like Abeclib 150 mg (Abemaciclib) Tablet accessible and affordable. Their services include:

• Affordable Procurement: Competitive pricing for hospitals and clinics.
• Global Logistics: Reliable delivery to Asia, Africa, Europe, and beyond.
• Expert Directory: Access to oncology specialists via www.oncosolution.com.

With core values of innovation, compassion, and integrity, Onco Solution bridges gaps in cancer care by ensuring timely access to critical therapies.

Technical Specifications

• Active Ingredient: Abemaciclib 150 mg
• Dosage Form: Film-coated oral tablet
• Storage: Store below 30°C in a dry environment.
• Prescription Requirement: Oncologist supervision mandatory.

Patient-Centric Advantages

• Home-Based Care: Oral administration reduces hospital visits.
• Tailored Regimens: Combines with endocrine therapies for personalized treatment.
• Improved Tolerability: Lower risk of severe side effects compared to chemotherapy.

Global Accessibility & Partnerships

Through collaboration with Eskayef Pharmaceuticals Ltd., Onco Solution ensures Abeclib 150 mg (Abemaciclib) Tablet reaches underserved regions, prioritizing:

• Affordability: Cost-effective pricing for low-resource settings.
• Quality Compliance: Adherence to WHO-GMP and ISO standards.
• Education: Resources for patients and providers on treatment protocols.

Ordering Information

Healthcare providers can procure Abeclib 150 mg (Abemaciclib) Tablet via Onco Solution. Visit www.oncosolution.com for bulk orders, clinical support, and access to their global oncology network.

Conclusion

Abeclib 150 mg (Abemaciclib) Tablet redefines HR+/HER2- breast cancer management through precision targeting and global accessibility. Trust Eskayef Pharmaceuticals Ltd. for quality manufacturing and Onco Solution for seamless distribution. For orders or clinical guidance, connect with Onco Solution today.